Fig. 2From: Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinomaKaplan–Meier curves of (a) time to treatment failure, (b) progression-free-survival, and (c) overall survival in the two groups divided according to the 6-week COP-NLRBack to article page